Literature DB >> 17786363

Expression of ECRG4 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma.

Yoichiro Mori1, Hideyuki Ishiguro, Yoshiyuki Kuwabara, Masahiro Kimura, Akira Mitsui, Horoki Kurehara, Ryota Mori, Keisuke Tomoda, Ryo Ogawa, Takeyasu Katada, Koshiro Harata, Yoshitaka Fujii.   

Abstract

In this study, we examined the expression of esophageal cancer-related gene 4 (ECRG4) mRNA and evaluated its clinical significance in esophageal squamous cell carcinoma (ESCC). ECRG4 mRNA expression was quantified by real-time RT-PCR in 63 ESCC and corresponding normal esophageal mucosal samples. ECRG4 mRNA expression levels were significantly lower in ESCC tissues compared with corresponding normal esophageal mucosa (P<0.0001), in patients with locally invasive T2-4 tumors compared with less invasive T1 tumors (P=0.0229) and in stage 4 tumors compared with stage 0-3 tumors (P=0.0120). Furthermore, low ECRG4 mRNA expression levels were associated with significantly shorter survival after surgery compared with high ECRG4 mRNA expression levels (P=0.0150) in ESCC patients. On the basis of multivariate analysis, we conclude that ECRG4 mRNA expression level could be a candidate for an independent prognostic factor for ESCC patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786363

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  38 in total

1.  Cell surface localization and release of the candidate tumor suppressor Ecrg4 from polymorphonuclear cells and monocytes activate macrophages.

Authors:  Andrew Baird; Raul Coimbra; Xitong Dang; Nicole Lopez; Jisook Lee; Michael Krzyzaniak; Robert Winfield; Bruce Potenza; Brian P Eliceiri
Journal:  J Leukoc Biol       Date:  2012-03-06       Impact factor: 4.962

2.  Downregulated ECRG4 is associated with poor prognosis in renal cell cancer and is regulated by promoter DNA methylation.

Authors:  Liya Luo; Jianting Wu; Jun Xie; Lingling Xia; Xuemin Qian; Zhiming Cai; Zesong Li
Journal:  Tumour Biol       Date:  2015-08-15

3.  Processing of proaugurin is required to suppress proliferation of tumor cell lines.

Authors:  Akihiko Ozawa; Adam N Lick; Iris Lindberg
Journal:  Mol Endocrinol       Date:  2011-03-24

Review 4.  Potential functions of esophageal cancer-related gene-4 in the cardiovascular system.

Authors:  Rui Zhou; Yuanshu Liu; Wenjun Huang; Xitong Dang
Journal:  Front Med       Date:  2019-08-29       Impact factor: 4.592

5.  Monitoring Neutrophil-Expressed Cell Surface Esophageal Cancer Related Gene-4 after Severe Burn Injury.

Authors:  Todd W Costantini; Raul Coimbra; Nicole E Lopez; Jeanne G Lee; Bruce Potenza; Alan Smith; Andrew Baird; Brian P Eliceiri
Journal:  Surg Infect (Larchmt)       Date:  2015-10-13       Impact factor: 2.150

6.  Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma.

Authors:  Linwei Li; Wenyu Wang; Xiaoyan Li; Tianhui Gao
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

7.  Soluble purified recombinant C2ORF40 protein inhibits tumor cell growth in vivo by decreasing telomerase activity in esophageal squamous cell carcinoma.

Authors:  Linwei Li; Xiaoyan Li; Wenyu Wang; Tianhui Gao; Yun Zhou; Shixin Lu
Journal:  Oncol Lett       Date:  2016-08-02       Impact factor: 2.967

8.  Genome-wide census and expression profiling of chicken neuropeptide and prohormone convertase genes.

Authors:  K R Delfino; B R Southey; J V Sweedler; S L Rodriguez-Zas
Journal:  Neuropeptides       Date:  2009-12-14       Impact factor: 3.286

9.  Overexpression of candidate tumor suppressor ECRG4 inhibits glioma proliferation and invasion.

Authors:  Wei Li; Xinrui Liu; Bo Zhang; Dongxue Qi; Lihong Zhang; Yuhong Jin; Hongfa Yang
Journal:  J Exp Clin Cancer Res       Date:  2010-07-04

10.  ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma.

Authors:  Silke Götze; Valeska Feldhaus; Thilo Traska; Marietta Wolter; Guido Reifenberger; Andrea Tannapfel; Cornelius Kuhnen; Dirk Martin; Oliver Müller; Sonja Sievers
Journal:  BMC Cancer       Date:  2009-12-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.